Advertisement

Irish Journal of Medical Science (1971 -)

, Volume 188, Issue 1, pp 43–53 | Cite as

Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases

  • Cathal O’Leary
  • Megan Greally
  • John McCaffrey
  • Peter Hughes
  • Leo L. P. Lawler
  • Martin O’Connell
  • Tony Geoghegan
  • Cormac FarrellyEmail author
Original Article
  • 120 Downloads

Abstract

Background

Liver metastases are the commonest cause of death for patients with colorectal cancer. Growing evidence supports the use of selective internal radiation therapy (SIRT) in combination with conventional chemotherapy regimens for liver-only or liver-dominant unresectable metastatic colorectal cancer.

Aims

To measure and evaluate outcomes of the first 20 consecutive patients with unresectable colorectal liver metastasis selected for SIRT in addition to their chemotherapy at a single Irish institution.

Methods

Retrospective case series was performed. Patient charts and medical records were reviewed.

Results

All 20 patients (100%) selected for angiographic workup were subsequently successfully treated with radioembolization. All patients were discharged 1 day post-SIRT. At initial imaging evaluation, 12 (60%) had a partial response in their liver, 2 (10%) had stable disease, and 6 (30%) had liver-specific progressive disease. Median follow up was 10 months (range 6–26). At last follow up, 14 (70%) patients were alive and 6 (30%) deceased. Most recent imaging demonstrated 2 (10%) with a complete response, 7 (35%) had a partial response, 2 (10%) had stable disease, and 9 (45%) had progressive disease within their liver. One patient was downstaged to hepatic resection, and one with a complete hepatic response had his primary sigmoid tumor resected 11 months post-SIRT.

Conclusions

SIRT is a safe and effective therapy for certain patients with unresectable colorectal liver metastases. This case series supports our opinion that selected patients should be offered SIRT in concert with their medical oncologist, concomitant with their chemotherapy. Larger multi-center studies are required to more clearly define the patient groups that will derive most benefit from SIRT.

Keywords

Colorectal liver metastases Cytoreduction Interventional oncology Interventional radiology Intra-arterial brachytherapy Localized therapy Molecular genetics Radioembolization Radiosensitization Radiotherapy Regional therapy SIRT Unresectable liver metastases 

Notes

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All patients consented to their procedures.

For this type of study, formal (research participation) consent is not required.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    National Cancer Registry (2016) Cancer in Ireland 1994–2014: annual report of the National Cancer Registry. NCR, CorkGoogle Scholar
  2. 2.
    Van Cutsem E, Cervantes A, Nordlinger B et al (2014) Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9.  https://doi.org/10.1093/annonc/mdu260 CrossRefGoogle Scholar
  3. 3.
    Bengtsson G, Carlsson G, Hafström L, Jönsson PE (1981) Natural history of patients with untreated liver metastases from colorectal cancer. Am J Surg 141(5):586–589CrossRefGoogle Scholar
  4. 4.
    Wagner JS, Adson MA, Van Heerden JA et al (1984) The Natural History of Hepatic Metastases from Colorectal Cancer. Ann Surg 199(5):502–508CrossRefGoogle Scholar
  5. 5.
    Sasson AR, Sigurdson ER (2002) Surgical treatment of liver metastases. Semin Oncol 29(2):107–118CrossRefGoogle Scholar
  6. 6.
    Lewandowski RJ, Memon K, Mulcahy MF, Hickey R, Marshall K, Williams M, Salzig K, Gates VL, Atassi B, Vouche M, Atassi R, Desai K, Hohlastos E, Sato K, Habib A, Kircher S, Newman SB, Nimeiri H, Benson AB, Salem R (2014) Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging 41(10):1861–1869.  https://doi.org/10.1007/s00259-014-2799-2 CrossRefGoogle Scholar
  7. 7.
    Macdonald JS (1999) Adjuvant therapy of colon cancer. CA Cancer J Clin 49(4):202–219CrossRefGoogle Scholar
  8. 8.
    Manfredi S, Lepage C, Hatem C et al (2006) Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 244(2):254–259.  https://doi.org/10.1097/01.sla.0000217629.94941.cf CrossRefGoogle Scholar
  9. 9.
    Chun YS, Vauthey JN (2007) Extending the frontiers of resectability in advanced colorectal cancer. Eur J Surg Oncol 33(Suppl 2):S52–S58.  https://doi.org/10.1016/j.ejso.2007.09.026 CrossRefGoogle Scholar
  10. 10.
    Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Ragué J, Serrano T, Fabregat J (2007) Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon rectum 50(4):478–488.  https://doi.org/10.1007/s10350-006-0817-6 CrossRefGoogle Scholar
  11. 11.
    Tomlinson JS Jarnagin WR, DeMatteo RP et al (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29):4575–4580.  https://doi.org/10.1200/JCO.2007.11.0833 CrossRefGoogle Scholar
  12. 12.
    Ruers T, Van Coevorden F, Punt CJA, et al. (2017) Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. JNCI J Natl Cancer Inst 109(9) doi: https://doi.org/10.1093/jnci/djx015
  13. 13.
    Tabernero J, Van Cutsem E et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50:320–331.  https://doi.org/10.1016/j.ejca.2013.09.013 CrossRefGoogle Scholar
  14. 14.
    Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJA, Strickland AH, Wilson G, Ciuleanu TE, Roman L, van Cutsem E, Tian Y, Sidhu R (2014) Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 25:107–116.  https://doi.org/10.1093/annonc/mdt523 CrossRefGoogle Scholar
  15. 15.
    Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–985Google Scholar
  16. 16.
    Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:1552–1563.  https://doi.org/10.1016/j.ijrobp.2004.09.004 CrossRefGoogle Scholar
  17. 17.
    Hendlisz A, Van den Eynde M, Peeters M et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:3687–3694.  https://doi.org/10.1200/JCO.2010.28.5643 CrossRefGoogle Scholar
  18. 18.
    Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35:1066–1073.  https://doi.org/10.1007/s00270-011-0234-7 CrossRefGoogle Scholar
  19. 19.
    Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:324–331.  https://doi.org/10.1038/sj.bjc.6605770 CrossRefGoogle Scholar
  20. 20.
    Benson AB, Geschwind JF, Mulcahy MF et al (2013) Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 49:3122–3130.  https://doi.org/10.1016/j.ejca.2013.05.012 CrossRefGoogle Scholar
  21. 21.
    Mulcahy MF, Lewandowski RJ, Ibrahim SM, Sato KT, Ryu RK, Atassi B, Newman S, Talamonti M, Omary RA, Benson A III, Salem R (2009) Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 115:1849–1858.  https://doi.org/10.1002/cncr.24224 CrossRefGoogle Scholar
  22. 22.
    van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, van Buskirk M, Cade DN, Thurston K, Gibbs P (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34(15):1723–1731.  https://doi.org/10.1200/JCO.2015.66.1181 CrossRefGoogle Scholar
  23. 23.
    Sharma RA, Van Hazel GA, Morgan B et al (2007) Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25(9):1099–1106.  https://doi.org/10.1200/JCO.2006.08.7916 CrossRefGoogle Scholar
  24. 24.
    Wang L (2010) Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine. Hepat Med 2:111–124.  https://doi.org/10.2147/HMER.S9052 CrossRefGoogle Scholar
  25. 25.
    SIR-Spheres® microspheres training program: physicians and institutions. Sirtex Web site. Available at: http://www.sirtex.com/files/TRN-US-05.pdf. Accessed 17 May 2017
  26. 26.
    Gil-Alzugaray B, Chopitea A, Iñarrairaegui et al (2013) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57:1078–1087.  https://doi.org/10.1002/hep.26191 CrossRefGoogle Scholar
  27. 27.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247.  https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefGoogle Scholar
  28. 28.
    Ingold JA, Reed GB, Kaplan HS et al (1965) Radiation hepatitis. Am J Roentgenol Radium Therapy Nucl Med 93:200–208Google Scholar
  29. 29.
    Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122CrossRefGoogle Scholar
  30. 30.
    Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, ten Haken RK (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76:S94–100.  https://doi.org/10.1016/j.ijrobp.2009.06.092 CrossRefGoogle Scholar
  31. 31.
    Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A (2011) General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 34(3):337–341.  https://doi.org/10.1097/COC.0b013e3181ec61bb CrossRefGoogle Scholar
  32. 32.
    Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF (2013) Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol 36(3):613–622.  https://doi.org/10.1007/s00270-013-0600-8 CrossRefGoogle Scholar
  33. 33.
    Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R (2009) Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 74:1494–1500.  https://doi.org/10.1016/j.ijrobp.2008.10.005 CrossRefGoogle Scholar
  34. 34.
    Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, Chopitea A, Iñarrairaegui M, Arbizu J, Bilbao JI (2008) Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112:1538–1546.  https://doi.org/10.1002/cncr.23339 CrossRefGoogle Scholar
  35. 35.
    Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KVN (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22:1697–1705.  https://doi.org/10.1016/j.jvir.2011.08.013 CrossRefGoogle Scholar
  36. 36.
    Salem R, Lewandowski RJ, Kulik L et al (2011) Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507. e2.  https://doi.org/10.1053/j.gastro.2010.10.049 CrossRefGoogle Scholar
  37. 37.
    Cortesi E, Masi G, Mancini M, Caponnetto S, Urbano F, Mosillo C, Scagnoli S, Notarianni E, Pelle G, Vivaldi C, Falcone A, Cianni R (2016) P-158radioembolization (SIRT) as a consolidation treatment in colorectal liver metastases after first line chemotherapy: efficacy safety. Ann Oncol 27(Suppl 2):ii47.  https://doi.org/10.1093/annonc/mdw199.152 CrossRefGoogle Scholar
  38. 38.
    Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Liechtenstein M (2005) A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 5:132.  https://doi.org/10.1186/1471-2407-5-132 CrossRefGoogle Scholar
  39. 39.
    van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol 27:4089–4095.  https://doi.org/10.1200/JCO.2008.20.8116 CrossRefGoogle Scholar
  40. 40.
    Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr, Loehr SP, Overton C, Meranze S, Niedzwiecki J, Sailer S (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425.  https://doi.org/10.1016/j.ijrobp.2005.12.051 CrossRefGoogle Scholar
  41. 41.
    Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, la Fougere C, Murthy R, Helmberger TK, Reiser MF (2008) Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 19:1187–1195.  https://doi.org/10.1016/j.jvir.2008.05.013 CrossRefGoogle Scholar
  42. 42.
    Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL (2012) Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 23:96–105.  https://doi.org/10.1016/j.jvir.2011.09.028 CrossRefGoogle Scholar
  43. 43.
    Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422.  https://doi.org/10.1093/annonc/mdw235 CrossRefGoogle Scholar
  44. 44.
    Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711–1720CrossRefGoogle Scholar
  45. 45.
    Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85.  https://doi.org/10.1002/jso.20141 CrossRefGoogle Scholar
  46. 46.
    Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A, van Hazel G, Sharma RA, Adams R, Bateman A, Blesing C, Brown E, Chau I, Cummins S, Cunningham D, Falk S, Hadaki M, Hall M, Hickish T, Hornbuckle J, Lofts F, Lowndes S, Mayer A, Metcalfe M, Middleton G, Mills J, Montazeri A, Muirhead R, Polychronis A, Purcell C, Ross P, Sharma RA, Sherwin L, Smith D, Soomal R, Swinson D, Walther A, Wasan H, Weaver A, Wilson C, Wilson G, Amin P, Angelelli B, Balosso J, Beny A, Bloomgarden D, Boucher E, Brown M, Bruch HR, Bui J, Burge M, Cardaci G, Carlisle J, Chai S, Chen YJ, Chevallier P, Chuong M, Clarke S, Coveler A, Craninx M, Delanoit T, Deleporte A, Eliadis P, Facchini F, Ferguson T, Ferrante M, Findlay M, Frenette G, Frick J, Ganju V, Garofalo M, Geboes K, Gehbauer G, George B, Geva R, Gibbs P, Gordon M, Gregory K, Gulec S, Hannigan J, van Hazel G, Heching N, Heinemann V, Helmberger T, Hendlisz A, Hendrickx K, Holtzman M, Isaacs R, Jackson C, James P, Kaiser A, Karapetis C, Kaubisch A, Ko YD, Kröning H, Lammert F, Liauw W, Limentani S, Louafi S, de Man M, Margolis J, Martin R, Martoni A, Marx G, Matos M, Monsaert E, Moons V, Nott L, Nusch A, O'Donnell A, Ozer H, Padia S, Pavlakis N, Peeters M, Perez D, Pluntke S, Polus M, Powell A, Pracht M, Price T, Ransom D, Rebischung C, Ricke J, Ridwelski K, Riera-Knorrenschild J, Riess H, Rilling W, Robinson B, Rodríguez J, Sanchez F, Sauerbruch T, Savin M, Scheidhauer K, Schneiderman E, Seeger G, Segelov E, Schmueli ES, Shani A, Shannon J, Sharma N, Shibata S, Singhal N, Smith D, Smith R, Stemmer S, Stötzer O, Strickland A, Taieb J, Tatsch K, Terrebonne E, Tichler T, Vehling-Kaiser U, Vera-Garcia R, Vogl T, Walpole E, Wang E, Whiting S, Wolf I, Ades S, Aghmesheh M, Angelelli B, Auber M, Ayala H, Beny A, Bloomgarden D, Boland P, Bouche E, Bowers C, Bremer C, Bui J, Burge M, Carlisle J, Casado AR, Chai S, Chuong M, Cooray P, Crain M, de Wit M, Deleporte A, Dowling K, Durand A, Facchini F, Faivre S, Feeney K, Ferguson T, Ferru A, Findlay M, Fragoso M, Frenette G, Frick J, Ganju V, Geva R, Gibbs P, Granetto C, Hammel P, van Hazel G, Heching N, Hendlisz A, Hendrickx K, Holtzman M, Issacs R, Iyer R, Jackson C, Kaiser A, Kaubisch A, Kim YH, Kröning H, Liang JT, Lim L, Limentani S, Liu JH, Louafi S, de Man M, Masi G, Matos M, Monsaert E, Mosconi S, Nott L, Numico G, O'Donnell A, Peeters M, Polus M, Pracht M, Ratner L, Rebischung C, Sae-Won H, Sanchez F, Shani A, Sharma N, Singh M, Singhal N, Smith D, Stoltzfus P, Strickland A, Taieb J, Tan I, Terrebonne E, Tichler T, Trogu A, Underhill C, Vera-Garcia R, Walpole E, Wang E, Westcott M (2017) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 18(9):1159–1171.  https://doi.org/10.1016/S1470-2045(17)30457-6 CrossRefGoogle Scholar
  47. 47.
    Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S (2017) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 3(2):211–219.  https://doi.org/10.1001/jamaoncol.2016.4227 CrossRefGoogle Scholar
  48. 48.
    Benson AB 3rd, Venook AP, Cederquist L et al (2017) Colon cancer, version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(3):370–398CrossRefGoogle Scholar
  49. 49.
    Hazel G, Heinemann V, Sharma N et al. (2017) Impact of primary tumour location on survival in patients with metastatic colorectal cancer receiving selective internal radiation therapy and chemotherapy as first-line therapy. ESMO 19th World Congress on Gastrointestinal Cancer, Ann Oncol Abs. LBA-006. doi:  https://doi.org/10.1093/annonc/mdx302.005
  50. 50.
    Garlipp B, Gibbs P, Van Hazel G. A. et al. (2017) REsect: blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± radioembolization (SIRT) in the randomized SIRFLOX trial. 2017 ASCO Annual meeting. J Clin Oncol 35, (suppl; abstr 3532). Doi: https://doi.org/10.1200/JCO.2017.35.15
  51. 51.
    Pardo F, Sangro B, Lee RC, Manas D, Jeyarajah R, Donckier V, Maleux G, Pinna AD, Bester L, Morris DL, Iannitti D, Chow PK, Stubbs R, Gow PJ, Masi G, Fisher KT, Lau WY, Kouladouros K, Katsanos G, Ercolani G, Rotellar F, Bilbao JI, Schoen M (2017) The post-SIR-Spheres surgery study (P4S): retrospective analysis of safety following hepatic resection or transplantation in patients previously treated with selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres. Ann Surg Oncol 24:2465–2473.  https://doi.org/10.1245/s10434-017-5950-z CrossRefGoogle Scholar
  52. 52.
    Ammori JB, D'Angelica MI, Fong Y, Cercek A, Dematteo RP, Allen PJ, Kingham TP, Paty PB, Jarnagin WR, Kemeny NE (2012) Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease. J Surg Oncol 106(8):953–958.  https://doi.org/10.1002/jso.23204 CrossRefGoogle Scholar
  53. 53.
    Bester L, Wasan H, Sangro B, Kennedy A, Pennington B, Sennfält K (2013) Selective internal radiotherapy (SIRT) using resin Yttrium-90 microspheres for chemotherapy-refractory metastatic colorectal cancer: a UK cost-effectiveness analysis. Value Health 16(7):A413.  https://doi.org/10.1016/j.jval.2013.08.515 CrossRefGoogle Scholar
  54. 54.
    Cosimelli M, Golfieri R, Pennington B, Sennfält K (2013) Selective internal radiotherapy (SIRT) using resin Yttrium-90 microspheres for chemotherapy-refractory metastatic colorectal cancer: an Italian cost-effectiveness analysis. Value Health 16(7):A409.  https://doi.org/10.1016/j.jval.2013.08.496 CrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2018

Authors and Affiliations

  1. 1.Radiology DepartmentMater Misericordiae University HospitalDublinIreland
  2. 2.Oncology DepartmentMater Misericordiae University HospitalDublinIreland

Personalised recommendations